Rs2227983

Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy.

Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study.

EGFR-targeted therapies in lung cancer: predictors of response and toxicity.

A two-stage case-control study of EGFR polymorphisms and breast cancer risk.

EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis.

Development of a fingerprinting panel using medically relevant polymorphisms.

Genetic polymorphisms in the EGFR (R521K) and estrogen receptor (T594T) genes, EGFR and ErbB-2 protein expression, and breast cancer risk in Tunisia.

Population based allele frequencies of disease associated polymorphisms in the Personalized Medicine Research Project.

Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.